<DOC>
	<DOCNO>NCT01406249</DOCNO>
	<brief_summary>The aim study elucidate efficacy safety XP SP first-line treatment Advanced Gastric Cancer .</brief_summary>
	<brief_title>XParTS II : Capecitabine/CDDP ( XP ) S-1/CDDP ( SP ) First-line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>XP SP either standard treatment advance gastric cancer . The aim study elucidate efficacy safety Capecitabine/Cisplatin S-1/Cisplatin first-line treatment Advanced Gastric Cancer .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically confirm gastric adenocarcinoma unresectable metastatic recurrent disease 2 . Lesions confirm image within 28 day registration ( require measurable lesion define RECIST version 1.1 ) 3 . No previous chemotherapy radiotherapy . However , adjuvant chemotherapy allow case 6 month end adjuvant chemotherapy 4 . ECOG Performance Status 0 2 5 . Life expectancy least 3 month registration 6 . Written inform consent 7 . Age 20 74 year either gender 8 . Adequate Major organ function within 14 day registration 1 . Positive HER2 status 2 . Previous history fluoropyrimidines therapy within 6 month prior registration 3 . Previous treatment platinum agent 4 . Previous history serious hypersensitivity fluoropyrimidines platinum agent 5 . Previous history adverse reaction suggestive dihydropyrimidine dehydrogenase ( DPD ) deficiency 6 . More one cancer time one cancer different time separate 5year diseasefree interval . However , multiple active cancer include carcinoma situ skin cancer determine cured result treatment . 7 . Obvious infection inflammation ( pyrexia ≥ 38.0˚C ) 8 . Active hepatitis 9 . Heart disease serious require hospitalization , history disease within past year 10 . Having complication serious require hospitalization ( intestinal paralysis , intestinal obstruction , interstitial pneumonia pulmonary fibrosis , poorly control diabetes mellitus , renal failure , liver disorder , hepatic cirrhosis ) 11 . Being treated need treatment flucytosine , phenytoin warfarin potassium 12 . Chronic diarrhea ( watery stool ≥4 times/day ) 13 . Active gastrointestinal bleeding 14 . Body cavity fluid require drainage treatment 15 . Clinical suspicion previous history metastasis brain meninges 16 . Women pregnant , breastfeeding , potentially ( hop become ) pregnant 17 . Unwillingness practice contraception 18 . Poor oral intake 19 . Psychiatric disorder may need treated psychotropics 20 . Otherwise determined investigator site principal investigator unsuitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>unresectable gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>StageIV gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>XP</keyword>
	<keyword>SP</keyword>
</DOC>